Central VF progression faster in NTG with autonomic dysfunction

Article

Central visual field (VF) progression is faster in patients with normal tension glaucoma (NTG) and lower heart-rate variability than it is in NTG patients with higher heart-rate variability, according to recently published research.

Central visual field (VF) progression is faster in patients with normal tension glaucoma (NTG) and lower heart-rate variability than it is in NTG patients with higher heart-rate variability, according to research published online before print in Investigative Ophthalmology and Visual Science.

Lower heart-rate variability indicates autonomic dysfunction with sympathetic predominance, note the researchers, who add that intraocular pressure-independent risk factors such as migraine, orthostatic hypotension and autonomic dysfunction are related to central VF progression.

The Seoul, South Korea, investigators retrospectively studied 48 eyes with NTG in more than 7 VF tests during at least 5 years of follow-up. Rheumatology assessments determined their heart-rate variability.

The scientists organized patients into heart-rate-variability groups based on the standard deviation value of the qualified normal-to-normal intervals of the assessment. They divided VF into central and peripheral regions as well as superior and inferior regions. Using a linear mixed model, they examined each group’s rates of change in the mean thresholds of each designated region. They also examined potential clinical factors associated with central VF progression.

The lowest and highest heart-rate-variability groups showed similar stages of glaucoma damage, as revealed by baseline VF. The two groups also had similar mean global rate of VF changes, with only the rate of VF change in the central and superior central regions differing significantly. Significantly associated with central VF progression were baseline VF pattern standard deviation, migraine, orthostatic hypotension, and lower heart-rate-variability.

To view the abstract of the study, visit the journal's website.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.